Predicting Heart Problems in Patients with Peripheral Artery Disease
Author Information
Author(s): Li Ben, Shaikh Farah, Younes Houssam, Abuhalimeh Batool, Chin Jason, Rasheed Khurram, Zamzam Abdelrahman, Abdin Rawand, Qadura Mohammad
Primary Institution: University of Toronto
Hypothesis
Can circulating immunomodulatory proteins predict major adverse cardiovascular events in patients with peripheral artery disease?
Conclusion
Galectin-1, galectin-9, and alpha-1-microglobulin are independently associated with major adverse cardiovascular events in patients with peripheral artery disease.
Supporting Evidence
- 63 individuals (16%) developed major adverse cardiovascular events during the follow-up.
- Galectin-1, alpha-1-microglobulin, and galectin-9 were significantly elevated in patients with MACE.
- The study involved a cohort of 406 patients, including 254 with PAD.
- Patients with higher levels of the identified proteins had a lower freedom from MACE.
Takeaway
Doctors can check certain proteins in the blood to see if patients with leg artery problems are at risk of serious heart issues.
Methodology
A prognostic study with 406 patients, measuring plasma concentrations of 17 proteins and following them for two years.
Limitations
The study was conducted at a single center, had a 2-year follow-up, and was not powered to assess individual MACE components.
Participant Demographics
Mean age 68.8 years, 33% female.
Statistical Information
P-Value
p = 0.012 for galectin-1, p = 0.019 for alpha-1-microglobulin, p = 0.033 for galectin-9.
Confidence Interval
95% CI 1.09–1.92 for galectin-1, 95% CI 1.06–1.63 for alpha-1-microglobulin, 95% CI 1.02–1.78 for galectin-9.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website